Hematocrit level and associated mortality in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 10, Issue 3, 1999, Pages 610-619

  Ma, Jennie Z ^a   Ebben, Jim ^b   Xia, Hong ^b   Collins, Allan J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ADULT; AGED; ARTICLE; COGNITION; CORRELATION FUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

EID: 0033052842     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Eknoyan G, Levin N: Clinical Practice Guidelines: Final Guideline Summaries from the Work Groups of the National Kidney Foundation - Dialysis Outcomes Quality Initiative, New York, National Kidney Foundation, 1997
2. Eschbach J, Abdulhadi MBJ, Delano B, Downing M, Egrie J, Evans R, Friedman E, Graber S, Haley R, Korbet S, Krantz S, Lundin A, Nissenson A, Ogden D, Paganini E, Rader B, Rutsky E, Stivelman J, Stone W, Teschan P, Van Stone J, Van Wyck D, Zuckerman K, Adamson J: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a Phase III multicenter clinical trial. Ann Intern Med 111: 992-1000, 1989
3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61, 1996
4. Ritz E, Zeier M, Schneider P, Jones E: Cardiovascular mortality of patients with polycystic kidney disease on dialysis: Is there a lesson to learn? Nephron 66: 125-128, 1994
5. Paganini E: In search of an optimal hematocrit level in dialysis patients: Rehabilitation and quality-of-life implications. Am J Kidney Dis 24: S10-S16, 1994
6. Suzuki M, Tsutsui M, Yokoyama A, Hirasawa Y: Normalization of hematocrit with recombinant human erythropoietin in chronic hemodialysis patients does not fully improve their exercise tolerance abilities. Artif Organs 19: 1258-1261, 1995
7. Madore F, Lowrie E, Brugnara C, Lew N, Lazarus M, Bridges K, Owen W: Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 8: 1921-1929, 1997
8. Department of Health, Education, and Welfare: Federal Health Insurance for the Aged and Disabled, Department of Health, Education and Welfare, Federal Register. Part II(40 (127)), 27782-27793. 7-1-1975. Washington, DC (Reference type: Bill/Resolution)
9. U.S.Renal Data System: USRDS 1997 Annual Data Report, Bethesda, MD, 1997
10. Powe NR, Griffiths RI, Greer JW: Early dosing practices and effectiveness of recombinant human erythropoietin. Kidney Int 43: 1125-1133, 1993
11. Powe NR, Griffiths RI, Watson AJ, Anderson GF, de Lissovoy G, Greer JW, Herbert RJ, Milam RA, Whelton PK: Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 4: 1455-1465, 1994
12. Collins AJ, Ma J, Constantini E, Everson S: Dialysis unit and patient characteristics associated with reuse practices and mortality: 1989-1993. J Am Soc Nephrol 9: 2108-2117, 1998
13. Cox D: Regression models and life-tables. J Roy Statistical Soc Series B 34: 187-220, 1972
14. Brookmeyer R, Gail MH: Biases in prevalent cohorts. Biometric 43: 739-749, 1987
15. Muirhead N, Hodsman AB: Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. Nephrol Dial Transplant 5: 232-234, 1990
16. Douglas SW, Adamson JW: The anemia of chronic disorders: Studies of marrow regulation and iron metabolism. Blood 45: 55-65, 1975
17. Almond MK, Tailor D, Marsh RP, Raftery MJ, Cunningham J: Increased erythropoietin requirements in patients with failed renal transplants returning to a dialysis programme. Nephrol Dial Transplant 9: 270-273, 1994
18. Danielson B: R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10: 69-73, 1995
19. Drucke TB: R-HuEPO hyporesponsiveness: Who and why? Nephrol Dial Transplant 10: 62-68, 1995
20. Patruta SI, Edlinger R, Sunder-Plassmann G, Horl WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9: 655-663, 1998
21. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 9: 869-876, 1998
22. Owen W, Lew N, Liu Y, Lowrie E, Lazarus M: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329: 1001-1006, 1993